These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3459351)

  • 21. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study.
    Manninen V; Elo MO; Frick MH; Haapa K; Heinonen OP; Heinsalmi P; Helo P; Huttunen JK; Kaitaniemi P; Koskinen P
    JAMA; 1988 Aug; 260(5):641-51. PubMed ID: 3164788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical results with gemfibrozil and background to the Helsinki Heart Study.
    Manninen V
    Am J Cardiol; 1983 Aug; 52(4):35B-38B. PubMed ID: 6351578
    [No Abstract]   [Full Text] [Related]  

  • 23. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
    Franceschini G; Sirtori M; Vaccarino V; Gianfranceschi G; Chiesa G; Sirtori CR
    J Lab Clin Med; 1989 Sep; 114(3):250-9. PubMed ID: 2504855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia.
    Tilly-Kiesi M; Tikkanen MJ
    J Lab Clin Med; 1992 Jul; 120(1):103-10. PubMed ID: 1613316
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Change in composition of high density lipoprotein during gemfibrozil therapy.
    Sorisky A; Ooi TC; Simo IE; Meuffels M; Hindmarsh JT; Nair R
    Atherosclerosis; 1987 Oct; 67(2-3):181-9. PubMed ID: 3118893
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive value for coronary heart disease of baseline high-density and low-density lipoprotein cholesterol among Fredrickson type IIa subjects in the Helsinki Heart Study.
    Manninen V; Koskinen P; Manttari M; Huttunen JK; Canter D; Frick HM
    Am J Cardiol; 1990 Sep; 66(6):24A-27A. PubMed ID: 2392990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity profile of gemfibrozil on the major plasma lipoprotein parameters.
    Sirtori CR; Franceschini G; Gianfranceschi G; Vaccarino V; Chiesa G; Maderna P; Bertoli M; Calabresi L
    Eur J Epidemiol; 1992 May; 8 Suppl 1():120-4. PubMed ID: 1505648
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
    Ashraf R; Amir K; Shaikh AR
    J Pak Med Assoc; 2005 Aug; 55(8):324-7. PubMed ID: 16164158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gemfibrozil improves abnormalities of lipid metabolism in patients on continuous ambulatory peritoneal dialysis: the role of postheparin lipases in the metabolism of high-density lipoprotein subfractions.
    Chan MK
    Metabolism; 1989 Oct; 38(10):939-45. PubMed ID: 2507877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of gemfibrozil treatment in hypercholesterolemia on low density lipoprotein (LDL) subclass distribution and LDL-cell interaction.
    Franceschini G; Lovati MR; Manzoni C; Michelagnoli S; Pazzucconi F; Gianfranceschi G; Vecchio G; Sirtori CR
    Atherosclerosis; 1995 Apr; 114(1):61-71. PubMed ID: 7605377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gemfibrozil in hyperlipidaemia: an open, single blind trial.
    Varthakavi PK; Turakhia DP; Sharma SS; Salgaonkar DS; Nihalani KD; Joshi VR
    J Assoc Physicians India; 1990 Feb; 38(2):136-40. PubMed ID: 2380132
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of gemfibrozil on serum lipid levels.
    Dahlén G; Gillnäs T; Børresen AL; Berg K; Ericson C
    Artery; 1980; 7(3):224-31. PubMed ID: 7008748
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Changes in serum and lipoprotein lipids, and apolipoprotein B and A-I, in patients with different types of primary hyperlipoproteinaemia treated with gemfibrozil.
    Sommariva D; Branchi A; Pini C; Scandiani L; Orlandi S; Fasoli A
    Int J Clin Pharmacol Res; 1988; 8(5):383-92. PubMed ID: 3068163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of nephrotic hyperlipoproteinemia with gemfibrozil.
    Groggel GC; Cheung AK; Ellis-Benigni K; Wilson DE
    Kidney Int; 1989 Aug; 36(2):266-71. PubMed ID: 2779095
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
    D'Agostino RB; Kannel WB; Stepanians MN; D'Agostino LC
    Am J Cardiol; 1992 Jan; 69(1):28-34. PubMed ID: 1729864
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia].
    Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G
    Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.
    Ojala JP; Helve E; Tikkanen MJ
    Cardiology; 1990; 77 Suppl 4():39-49. PubMed ID: 2073671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gemfibrozil plus cholestyramine in familial hypercholesterolaemia.
    Jones AF; Hughes EA; Cramb R
    Lancet; 1988 Apr; 1(8588):776. PubMed ID: 2895309
    [No Abstract]   [Full Text] [Related]  

  • 39. Effect of gemfibrozil on lipids, apoproteins, and postheparin lipolytic activities in normolipidemic subjects.
    Gnasso A; Lehner B; Haberbosch W; Leiss O; von Bergmann K; Augustin J
    Metabolism; 1986 May; 35(5):387-93. PubMed ID: 3458020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical results with gemfibrozil.
    Pickering JE
    Am J Cardiol; 1983 Aug; 52(4):39B-40B. PubMed ID: 6351579
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.